Hormonal Regulation of Cardiometabolic Health Study

The goal of this observational study is to understand how the loss of ovarian function after oophorectomy affects the health and well being of women aged 35-50. The study focuses on four areas: 1. Quality of life and embodied experience, 2. Cardiometabolic health, 3. Central nervous system function, and 4. Adipose tissue health and cellular function. Our primary goal is to understand the effects of oophorectomy on women's health in focus areas 1 to 3. To do this, we will compare women's health before surgery with follow up assessments at 1-2 months and 12 months after surgery. Some participants may start hormone replacement therapy (HRT) during follow up as part of their routine care; this is outside the study protocol. As an exploratory aim, we will examine whether 12 month outcomes-or the change from baseline to 12 months-differ between participants who begin HRT and those who do not. Focus area 4 provides an opportunity to explore how molecular and cellular mechanisms in adipose tissue respond to the loss of ovarian hormones. These analyses are exploratory and intended to offer mechanistic insight rather than clinical endpoints. Participants will: * undergo bilateral (or unilateral, if only one ovary remains) oophorectomy as part of their clinical treatment, * complete questionnaires and physiological measurements at three time points, * a subgroup will participate in qualitative interviews about their lived experience of surgical menopause, * and a subgroup will volunteer adipose tissue samples collected during surgery.

NCT Number	NCT07406412
Lead Sponsor	University of Jyvaskyla Collaborators: Wellbeing Services County of Central Finland, Wellbeing Services County of North Savo, Wellbeing Services County of Pirkanmaa, Wellbeing Services County of Southwest Finland, Wellbeing Services County of North Ostrobothnia, Hospital District of Helsinki and Uusimaa
Conditions	Menopause Surgical
Enrollment	120 participants
Start Date	2026-02-13
Primary Completion	2028-12-15 (estimated)
Study Completion	2028-12-15 (estimated)
Updated on ClinicalTrials.gov	2026-05-06